Core Laboratories N.V. (CLB) Key Metrics
CLB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $458.8M
- Enterprise value
- $630.1M
- P/E (TTM)
- 19.2 10-yr median 33.4
- Forward P/E
- 19.8
- PEG ratio
- 1.67
- Price / sales
- 0.9 10-yr median 2.3
- Price / book
- 1.8 10-yr median 8.1
- EV / EBITDA
- 10.3 10-yr median 19.8
- Dividend yield
- 0.40% $0.04 a year
- Beta
- 1.14
CLB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCLB valuation Price multiples at each fiscal year-end price.
CLB returns How much profit the business earns on the capital it uses.
CLB per-share figures Results divided by the shares outstanding at year-end.
CLB financial health Debt, liquidity and how easily interest is covered.
CLB efficiency & capital use Working capital cycle and where the cash goes.
CLB valuation history
CLB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CLB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CLB cash returned to shareholders
CLB price vs earnings per share
CLB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $745.4M | $825.4M | $839.3M | $948.9M | $1.04B | $1.19B | $1.68B | $2.65B | $4.85B | $5.30B |
| Enterprise value | $886.7M | $986.4M | $1.04B | $1.16B | $1.27B | $1.51B | $2.05B | $2.94B | $5.08B | $5.52B |
| P/E ratio | 25.1 | 26.3 | 22.9 | 48.8 | 52.8 | — | 16.5 | 33.4 | 58.3 | 82.9 |
| Price / sales | 1.4 | 1.6 | 1.6 | 1.9 | 2.2 | 2.4 | 2.5 | 3.8 | 7.3 | 8.9 |
| Price / book | 2.8 | 3.3 | 3.7 | 5.1 | 6.7 | 16.7 | 9.5 | 16.5 | 32.6 | 34.1 |
| Price / free cash flow | 33.4 | 19.0 | 59.1 | 64.4 | 45.2 | 25.9 | 25.0 | 29.5 | 46.0 | 44.1 |
| Price / operating cash flow | 20.1 | 14.6 | 33.9 | 38.0 | 28.5 | 20.6 | 18.8 | 23.7 | 39.0 | 40.2 |
| EV / sales | 1.7 | 1.9 | 2.0 | 2.4 | 2.7 | 3.1 | 3.1 | 4.2 | 7.7 | 9.3 |
| EV / EBITDA | 12.5 | 13.4 | 14.8 | 19.7 | 20.0 | 21.4 | 16.5 | 20.7 | 37.8 | 48.8 |
| EV / free cash flow | 39.8 | 22.7 | 73.2 | 78.4 | 55.3 | 32.7 | 30.5 | 32.6 | 48.1 | 45.9 |
| Earnings yield | 4.0% | 3.8% | 4.4% | 2.1% | 1.9% | −8.2% | 6.1% | 3.0% | 1.7% | 1.2% |
| Free cash flow yield | 3.0% | 5.3% | 1.7% | 1.6% | 2.2% | 3.9% | 4.0% | 3.4% | 2.2% | 2.3% |
| Dividend yield | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 1.0% | 5.8% | 3.7% | 2.0% | 1.8% |
| Shareholder yield (dividends + buybacks) | 1.9% | 0.9% | 0.5% | 0.6% | 1.0% | 1.3% | 6.0% | 3.9% | 2.4% | 1.9% |
| Share price at fiscal year-end | $16.03 | $17.31 | $17.66 | $20.27 | $22.31 | $26.51 | $37.67 | $59.66 | $109.55 | $120.04 |
| Per share | ||||||||||
| Revenue per share | $11.32 | $10.99 | $10.73 | $10.46 | $10.07 | $10.83 | $14.97 | $15.76 | $14.91 | $13.47 |
| Earnings per share | $0.64 | $0.66 | $0.77 | $0.42 | $0.42 | −$2.17 | $2.28 | $1.79 | $1.88 | $1.45 |
| Operating cash flow per share | $0.80 | $1.18 | $0.52 | $0.53 | $0.78 | $1.29 | $2.01 | $2.51 | $2.81 | $2.99 |
| Free cash flow per share | $0.48 | $0.91 | $0.30 | $0.31 | $0.49 | $1.02 | $1.51 | $2.03 | $2.38 | $2.72 |
| Cash per share | $0.49 | $0.40 | $0.32 | $0.33 | $0.38 | $0.31 | $0.25 | $0.29 | $0.33 | $0.33 |
| Book value per share | $5.72 | $5.28 | $4.73 | $3.94 | $3.35 | $1.59 | $3.98 | $3.62 | $3.36 | $3.52 |
| Tangible book value per share | $3.29 | $3.06 | $2.49 | $1.65 | $1.05 | −$0.81 | −$1.19 | −$1.61 | −$0.90 | −$0.76 |
| Dividends per share | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 | $0.28 | $2.19 | $2.19 | $2.19 | $2.15 |
| Capex per share | $0.32 | $0.27 | $0.22 | $0.22 | $0.29 | $0.26 | $0.50 | $0.49 | $0.42 | $0.27 |
| Debt per share | $3.53 | $3.78 | $4.53 | $4.75 | $5.36 | $7.27 | $8.55 | $6.75 | $5.51 | $5.26 |
| Shares outstanding | 46.5M | 47.7M | 47.5M | 46.8M | 46.7M | 45.0M | 44.6M | 44.5M | 44.3M | 44.2M |
| Change in shares outstanding | −2.5% | +0.3% | +1.5% | +0.3% | +3.8% | +0.7% | +0.4% | +0.5% | +0.3% | +2.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 11.5% | 13.2% | 17.9% | 11.4% | 17.3% | −78.3% | 60.2% | 51.4% | 54.7% | 97.1% |
| Return on invested capital (ROIC) | 8.2% | 9.7% | 12.0% | 7.0% | 6.6% | −13.0% | 19.4% | 21.8% | 24.5% | 19.1% |
| Return on assets (ROA) | 5.1% | 5.3% | 6.3% | 3.4% | 3.4% | −14.5% | 14.3% | 12.9% | 14.4% | 10.7% |
| Return on tangible assets | 6.3% | 6.5% | 7.6% | 4.1% | 4.2% | −21.2% | 18.8% | 19.1% | 21.0% | 16.6% |
| Free cash flow margin | 4.2% | 8.3% | 2.8% | 3.0% | 4.9% | 9.4% | 10.1% | 12.9% | 16.0% | 20.2% |
| Income quality (OCF / net income) | 1.25 | 1.80 | 0.68 | 1.28 | 1.85 | — | 0.88 | 1.41 | 1.49 | 2.06 |
| Financial health | ||||||||||
| Total debt | $164.0M | $180.1M | $215.4M | $222.4M | $250.3M | $327.0M | $381.8M | $300.2M | $244.1M | $232.2M |
| Cash & short-term investments | $22.7M | $19.2M | $15.1M | $15.4M | $17.7M | $13.8M | $11.1M | $13.1M | $14.4M | $14.8M |
| Net debt | $141.3M | $161.0M | $200.3M | $207.0M | $232.6M | $313.2M | $370.7M | $287.1M | $229.7M | $217.4M |
| Debt / equity | 0.62 | 0.71 | 0.96 | 1.21 | 1.60 | 4.57 | 2.15 | 1.87 | 1.64 | 1.50 |
| Debt / assets | 0.28 | 0.31 | 0.37 | 0.38 | 0.43 | 0.58 | 0.49 | 0.46 | 0.42 | 0.41 |
| Net debt / EBITDA | 1.99 | 2.19 | 2.84 | 3.53 | 3.65 | 4.44 | 2.97 | 2.03 | 1.71 | 1.92 |
| Current ratio | 2.02 | 2.32 | 2.53 | 2.05 | 2.08 | 1.85 | 1.98 | 2.25 | 1.98 | 1.79 |
| Quick ratio | 1.51 | 1.71 | 1.72 | 1.47 | 1.58 | 1.42 | 1.53 | 1.81 | 1.66 | 1.47 |
| Interest coverage | 4.8 | 4.7 | 4.1 | 3.6 | 4.9 | -5.3 | 6.6 | 8.9 | 10.5 | 7.4 |
| Working capital | $108.7M | $129.0M | $135.0M | $108.6M | $98.3M | $76.1M | $109.6M | $128.4M | $102.4M | $82.4M |
| Invested capital | $407.3M | $413.0M | $425.1M | $391.2M | $389.0M | $384.7M | $548.6M | $448.0M | $378.4M | $372.7M |
| Tangible asset value | $159.3M | $151.9M | $123.4M | $82.0M | $53.4M | −$32.5M | −$48.7M | −$71.6M | −$39.7M | −$33.7M |
| Net current asset value | −$97.1M | −$106.1M | −$133.5M | −$177.7M | −$230.8M | −$327.2M | −$371.3M | −$256.9M | −$228.7M | −$231.3M |
| Graham number | $9.06 | $8.85 | $9.06 | $6.07 | $5.64 | — | $14.31 | $12.06 | $11.92 | $10.70 |
| Graham net-net per share | −$3.68 | −$3.95 | −$4.49 | −$5.50 | −$6.41 | −$8.84 | −$10.14 | −$7.98 | −$6.89 | −$6.80 |
| Capital allocation | ||||||||||
| Dividends paid | $1.9M | $1.9M | $1.9M | $1.9M | $1.8M | $12.4M | $97.6M | $97.3M | $97.1M | $95.1M |
| Share buybacks (net) | $12.4M | $5.3M | $2.2M | $3.9M | $8.3M | $2.8M | $3.3M | $7.5M | $16.9M | $7.2M |
| Dividend payout ratio | 6.3% | 6.0% | 5.1% | 9.5% | 9.3% | — | 95.7% | 122.3% | 116.9% | 148.9% |
| Dividends + buybacks / free cash flow | 64.1% | 16.6% | 28.6% | 39.1% | 43.8% | 33.1% | 150.0% | 116.2% | 108.1% | 85.1% |
| Capex / revenue | 2.8% | 2.5% | 2.1% | 2.1% | 2.9% | 2.4% | 3.3% | 3.1% | 2.8% | 2.0% |
| Capex / operating cash flow | 39.8% | 23.1% | 42.7% | 40.9% | 37.0% | 20.5% | 24.9% | 19.4% | 15.1% | 8.9% |
| Capex / depreciation | 1.01 | 0.87 | 0.67 | 0.60 | 0.73 | 0.57 | 0.99 | 0.94 | 0.77 | 0.44 |
| Stock-based compensation / revenue | 1.4% | 0.7% | 2.7% | 1.6% | 4.1% | 1.5% | 3.1% | 4.9% | 3.5% | 3.7% |
| SG&A / revenue | 8.4% | 7.4% | 7.9% | 7.8% | 9.4% | 7.3% | 7.4% | 9.0% | 7.2% | 6.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 86.0 | 87.2 | 85.3 | 82.7 | 73.7 | 82.9 | 73.0 | 68.3 | 68.4 | 79.8 |
| Days of inventory on hand | 48.1 | 54.9 | 58.0 | 47.0 | 39.5 | 41.8 | 35.3 | 27.7 | 24.5 | 29.0 |
| Days payables outstanding | 30.3 | 28.5 | 34.8 | 33.6 | 24.9 | 27.8 | 28.3 | 29.1 | 27.6 | 26.1 |
| Cash conversion cycle (days) | 103.8 | 113.7 | 108.4 | 96.1 | 88.3 | 96.9 | 80.0 | 66.9 | 65.4 | 82.7 |
| Receivables turnover | 4.24 | 4.18 | 4.28 | 4.42 | 4.95 | 4.40 | 5.00 | 5.34 | 5.33 | 4.57 |
| Payables turnover | 12.04 | 12.80 | 10.48 | 10.87 | 14.65 | 13.14 | 12.91 | 12.55 | 13.24 | 13.97 |
| Inventory turnover | 7.59 | 6.64 | 6.29 | 7.76 | 9.24 | 8.72 | 10.34 | 13.17 | 14.89 | 12.58 |
| Asset turnover | 0.90 | 0.89 | 0.88 | 0.84 | 0.82 | 0.73 | 0.94 | 1.14 | 1.14 | 0.99 |
| Average receivables | $124.1M | $125.2M | $119.1M | $110.9M | $95.0M | $110.6M | $133.6M | $131.1M | $123.7M | $130.0M |
| Average payables | $35.9M | $34.0M | $39.7M | $37.8M | $26.4M | $29.3M | $38.4M | $41.4M | $37.7M | $33.6M |
| Average inventory | $56.9M | $65.6M | $66.1M | $52.9M | $41.8M | $44.2M | $47.9M | $39.5M | $33.5M | $37.3M |
| Intangibles / total assets | 19.3% | 17.9% | 18.1% | 18.5% | 18.5% | 19.0% | 29.8% | 35.8% | 32.2% | 33.0% |
Computed from CLB's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CLB valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Core Laboratories traded at 25.1 times earnings, against a 10-year median of 33.4. Based on the latest twelve months, the trailing P/E is 19.2 and the forward P/E is 19.8. Core Laboratories earned a return on equity of 11.5% and a return on invested capital of 8.2% in fiscal 2025. It ended the year with $164.0 million of debt and $22.7 million in cash and short-term investments, net debt of $141.3 million. It returned $14.3 million to shareholders: $1.9 million in dividends and $12.4 million in share buybacks, 64% of free cash flow. The share count rose 5.3% from 44.2M to 46.5M over 9 years.
See the CLB income statement, the CLB chart for price history, or the CLB stock overview for the latest quote and news.
CLB key metrics FAQ
What is Core Laboratories's P/E ratio?
Core Laboratories's trailing P/E ratio is 19.2 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 19.8. At the end of fiscal 2025 it was 25.1, compared with a 10-year median of 33.4.
What is Core Laboratories's EV/EBITDA?
Core Laboratories's enterprise value was 12.5 times EBITDA at the end of fiscal 2025 (enterprise value $886.7 million, EBITDA $71.1 million); the current EV/EBITDA is 10.3.
What is Core Laboratories's return on equity?
Core Laboratories's return on equity (ROE) was 11.5% in fiscal 2025: net income of $29.7 million on average shareholders' equity of $259.0 million.
What is Core Laboratories's ROIC?
Core Laboratories's return on invested capital was 8.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Core Laboratories have?
Core Laboratories had total debt of $164.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.62 and $141.3 million of net debt (1.99 times EBITDA).
What is Core Laboratories's dividend yield?
Core Laboratories's forward dividend yield is 0.40%. Core Laboratories paid $1.9 million in dividends in fiscal 2025 ($0.04 per share), a payout ratio of 6.3%.
Does Core Laboratories buy back its shares?
Yes. Core Laboratories spent $12.4 million on net share repurchases in fiscal 2025 Shares outstanding changed −2.5% over the year, to 46.5M..
What is Core Laboratories's free cash flow yield?
Core Laboratories generated $22.3 million of free cash flow in fiscal 2025, a free cash flow yield of 3.0% on its market value at year-end ($745.4 million).
What is Core Laboratories's current ratio?
Core Laboratories's current ratio was 2.02 at the end of fiscal 2025: current assets were 2.02 times current liabilities.